Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
5471 participants
INTERVENTIONAL
2021-07-26
2022-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this investigation is to describe the current levels of chronic disease risk factors in the adult population of New Caledonia aged from 18 to 64 years old. This study will also help to estimate prevalence of certain diseases (diabetes, hypercholesterolemia, renal failure), seroprevalence of arboviruses (dengue fever, Zika, chikungunya and Ross River) malaria as well as the seroprevalence of SARS-CoV-2.
Repeated regularly, these surveys allow the ASS-NC to capitalize on population indicators, to compare them according to socio-demographic characteristics, to identify groups at risk, to provide changes in health behaviors and to strengthen analytical capacities in order to adapt the guidelines for public policies and prevention programs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mapping the Health Status of the Population of French Polynesia: the MATAEA Project
NCT06133400
Prevalence of NCD Risk Factors in Kazakhstan
NCT05122832
Assessment of SARS-CoV-2 Seroprevalence in Detention
NCT04516512
Assessment of Routine Oral Screening Programs for New Prisoners
NCT03736070
Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico
NCT03794531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For this study the sampling is based on the 2019 population census, according to a 3-stage stratified sample design. In total, the main sample will consist of approximately 5,500 people (first phase) and the sub-sample will consist of 1,800 people (second phase).
The participation rate is estimated at 60%. Data collection will take place from February to May at the people's place drawn according to two steps:
* Firstly, investigators will carry out a questionnaire with the people who gave their informed consent as well as taking physical measurements: height, weight, abdominal circumference and blood pressure. In addition to the socio-demographic characteristics of the respondents, the questionnaire deals with several health topics: consumption of psychoactive substances, diet, physical activity, health status and access to care, screening, oral health, driving motor vehicle risk, sexual health, mental health, etc. The time taken to complete the questionnaire is estimated at one hour.
* Secondly, and for a sub-sample of 1,800 people, nurses will come back to the people's places who volunteer to take a venous blood test: blood sugar, total cholesterol, HbA1c, serum creatinine, CBC and serology of diseases transmitted by mosquitoes (dengue, chikungunya, Zika and Ross River, malaria).
All the data collected will be entered on a tablet in the eSTEPS application. The analysis of data (R Studio software) and the drafting of the report will be carried out by ASSNC staff. The first results are expected for the second half of 2022.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sample
questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure)
No interventions assigned to this group
Sub-sample - blood test
questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure) Blood samples
Blood sample
A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals between the ages of 18 and 64;
* Individuals residing in New Caledonia in so-called "ordinary" housing under their main residence at the last population census in 2019;
Exclusion Criteria
* Tourists and transients staying in New Caledonia for less than 6 months at the time of the investigation;
* People who are not intellectually fit to answer the questionnaire;
* Persons subject to guardianship, curatorship or any other legal incapacity;
* For the second phase of the study will be excluded people describing a febrile syndrome;
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
Pacific Community
OTHER
World Health Organization
OTHER
Institut de la Statitique et des Etudes Economiques Nouvelle Calédonie
UNKNOWN
Agence Sanitaire et Sociale de Nouvelle Calédonie
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Agence Sanitaire et Sociale Nouvelle Calédonie
Noumea, , New Caledonia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01260-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.